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Abstract
Background: Acute-on-chronic liver failure (ACLF) is characterized by the presence of acute decompensation (AD)
of cirrhosis, organ failure, and high short-term mortality rates. Hemodynamic dysfunction and activation of endogenous
vasoconstrictor systems are thought to contribute to the pathogenesis of ACLF. We explored whether copeptin, a
surrogate marker of arginine vasopressin, is a potential marker of outcome in patients admitted for AD or ACLF and
whether it might be of additional value to conventional prognostic scoring systems in these patients.
Methods: All 779 patients hospitalized for AD of cirrhosis from the CANONIC database with at least one serum sample
available for copeptin measurement were included. Presence of ACLF was defined according to the CLIF-consortium
organ failure (CLIF-C OF) score. Serum copeptin was measured in samples collected at days 0–2, 3–7, 8–14, 15–21, and
22–28 when available. Competing-risk regression analysis was applied to evaluate the impact of serum copeptin and
laboratory and clinical data on short-term survival.
Results: Serum copeptin concentration was found to be significantly higher in patients with ACLF compared with
those without ACLF at days 0–2 (33 (14–64) vs. 11 (4–26) pmol/L; p < 0.001). Serum copeptin at admission was shown
to be a predictor of mortality independently of MELD and CLIF-C OF scores. Moreover, baseline serum copeptin was
found to be predictive of ACLF development within 28 days of follow-up.
Conclusions: ACLF is associated with significantly higher serum copeptin concentrations at hospital admission compared
with those with traditional AD. Copeptin is independently associated with short-term survival and ACLF development in
patients admitted for AD or ACLF.
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Background
Acute decompensation (AD) of liver cirrhosis is charac-
terized by the occurrence of major complications of the
underlying liver disease and is the main cause of
hospitalization in cirrhotic patients. Acute-on-chronic
liver failure (ACLF) is a life-threatening syndrome that oc-
curs in patients with AD, and is characterized by organ
failure and often requires admission to the intensive care
unit (ICU) [1, 2]. Several non-evidence-based working
definitions have been proposed for ACLF [1, 3, 4]. In order
to define clear diagnostic criteria for this syndrome, the
European Association for the Study of the Liver—Chronic
Liver Failure (EASL-CLIF) consortium has performed the
Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC)
study [2]. In that study, a large cohort of patients hospi-
talized for AD were prospectively followed and ACLF
was found to be a distinct entity in patients with AD, as
it was characterized by the presence of organ failure
and a high short-term mortality rate [2]. The activation
of endogenous vasoconstrictor systems as an adaptive* Correspondence: j.c.kerbert@lumc.nl
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response to a decreased effective circulating blood volume
in cirrhotic patients with a hyperdynamic circulation is
thought to be associated with the development of organ
failure in ACLF [5, 6]. Conventional prognostic scoring
systems in cirrhosis, such as the Model for End-stage
Liver disease (MELD) and Child-Pugh score, do not ad-
equately account for risks associated with hemodynamic
derangement and organ failure. The recently developed
CLIF-consortium organ failure (CLIF-C OF) score has
been shown to be superior to the MELD and Child-Pugh
score in predicting prognosis in ACLF patients [7]. How-
ever, no marker reflecting the degree of activation of en-
dogenous vasoconstrictor systems has been included in
this score. Arginine vasopressin (AVP) is a hypothalamic
neurohormone which is secreted into the blood stream by
the neurohypophysis upon stimuli, such as hyperosmo-
larity, arterial hypotension, hypovolemia, and physio-
logical stress. Due to its role in both hemodynamic
homeostasis and the endogenous stress response, which
is also known to be associated with outcome in acute
illness, we hypothesized that the AVP system may be of
particular prognostic value in critically ill cirrhotic pa-
tients. Circulating AVP concentration as such is not
suitable due to its instability in serum and poor repro-
ducibility [8]. Copeptin is a stable cleavage product of
the C-terminal part of the AVP precursor and is se-
creted together with AVP in equimolar amounts [9, 10].
Copeptin is therefore generally considered a surrogate
marker for AVP. The present study aimed to assess in a
large study population of patients admitted for AD or
ACLF: 1) copeptin as a prognostic biomarker of short-
term survival and disease progression; and 2) whether
copeptin might be of additional prognostic value to conven-
tional prognostic scoring systems in cirrhosis and ACLF.
Methods
Study population
The present study is an ancillary study of the prospective
observational CANONIC study [2] (Additional file 1).
Written informed consent was obtained from each patient
included in that study and the study protocol conformed
to the ethical guidelines of the 1975 Declaration of Helsinki
as reflected a priori by the individual institution’s Medical
Ethics Committees as described elsewhere [2]. Between
February and September 2011, 1349 patients hospitalized
for AD of cirrhosis in 29 liver units in eight European
countries were included in the CANONIC study. The
HCB—IDIBAPS Biobank in Barcelona (Spain) manages
the CANONIC database and storage of biomaterials. For
779 patients included in the CANONIC study, a blood
sample drawn at hospital admission was available for
copeptin measurement and these patients were therefore
included in the present ancillary study. ACLF was defined
by the CLIF-C OF score [7], adapted from the original
chronic liver failure-sequential organ failure assessment
(CLIF-SOFA) score and specifically designed for the use in
cirrhotic patients with AD [2]. Demographics, clinical
characteristics, and laboratory measurements were
collected at the time of study enrolment. Patients
were followed-up until 28 days after study enrolment.
Survival data and events (mortality and liver trans-
plantation) were collected at set time points of
28 days and 3, 6, and 12 months of follow-up.
Copeptin measurements
Serum samples for copeptin measurements were obtained
at days 0–2 (n = 779), 3–7 (n = 205), 8–14 (n = 138), 15–21
(n = 12), and 22–28 (n = 71) after study enrolment and
stored at –80 °C. Serum copeptin measurements were per-
formed in 50 μL plasma samples using an immunoassay in
the chemiluminescence-coated tube format (B.R.A.H.M.S.,
Kryptor, GmbH, Hennigsdorf, Germany). The refer-
ence range of serum copeptin in healthy individuals is
1–12 pmol/L with median values of < 5 pmol/L [11, 12].
Statistical analysis
Discrete variables are shown as counts (percentage) and
continuous variables as mean ± standard deviation (SD).
Data with a skewed distribution are expressed as median
(interquartile range; IQR) and were log-transformed prior
to statistical analysis. A p value ≤ 0.05 was considered sta-
tistically significant.
The relation between ACLF grades and serum copep-
tin was analyzed using the Kruskal Wallis test and
Wilcoxon signed rank test when appropriate. Spearman’s
rank order correlation analysis was performed to explore
possible correlations between serum copeptin concentra-
tion and age, prognostic scoring systems, blood pressure,
and laboratory data. In survival analysis, competing-risk
regression models according to the method of Fine and
Gray [13] were used to assess the prognostic value of
copeptin on short-term (28- and 90-day) mortality. In
these models, liver transplantation was considered as a
competing risk factor in order to adjust for interdepend-
ence. Another competing-risk regression model was per-
formed in order to assess the impact of serum copeptin
changes over time on survival. To explore the impact of
serum copeptin levels on the disease course in patients
with ACLF, the definitions ‘improvement’, ‘worsening’,
and ‘steady’ ACLF course were applied as previously de-
scribed by Gustot et al. [14]. Variables with a p < 0.05 in
univariate regression analyses and age were included in
multivariate models. The MELD and CLIF-C OF scores
were separately evaluated with copeptin in multivariate
models in order to explore whether serum copeptin con-
centration is associated with outcome independently of
these scores. Individual variables included in these scores
were not included in multivariate models in order to avoid
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collinearity. To assess its predictive ability, the Concord-
ance (C-) index of serum copeptin for 28- and 90-day
mortality was calculated and its additional predictive value
to that of the MELD and CLIF-C OF scores was assessed.
A binary logistic regression model was performed in order
to identify the independent predictive factors of ACLF de-
velopment during the complete 28-days of follow-up.
Results
Patient characteristics
Baseline demographics and clinical characteristics are
shown in Table 1. A comparison between the baseline
characteristics of the study cohort of this ancillary
study and the whole CANONIC cohort is provided in
Additional file 2. At the time of enrolment in the study,
139 (17.8%) patients had ACLF (grade I, n = 80; grade
II, n = 51; grade III, n = 8). Serum copeptin at admission
was significantly higher in patients with ACLF com-
pared with those without (33 (14–64) vs. 11 (4–26)
pmol/L; p < 0.001). Significant differences between
these patient groups were also found for mean arterial
blood pressure (MAP), diastolic blood pressure (DBP),
and, as expected, the presence of clinical features such
as ascites, hepatic encephalopathy, systemic inflamma-
tory response syndrome (SIRS), sepsis, and bacterial in-
fections. Serum bilirubin, creatinine, and C-reactive
protein (CRP) concentrations, white blood cell count
(WBC), and international normalized ratio (INR) were
all significantly more elevated in the subgroup of pa-
tients with ACLF at enrolment compared with those
without. Consequently, prognostic scores (Child-Pugh,
MELD, CLIF-COF) were significantly higher in ACLF
(Table 1).
Baseline serum copeptin and association with kidney and
circulatory function and ACLF
Patients with ACLF grade III at enrolment displayed the
highest serum copeptin concentration at hospital admis-
sion. However, median serum copeptin concentrations
did not consistently increase along with the grade of
ACLF (grade I, 32 (15–66) pmol/L; grade II, 30 (14–53)
pmol/L; grade III, 88 (47–140) pmol/L). Serum copeptin
concentration did not significantly differ between grade I
and II (p = 0.460), but was significantly higher in grade
III compared with grade II (p = 0.029) and grade III
compared with grade I + II (p < 0.001). Figure 1 shows
the association of ACLF grades with serum copeptin
concentration and the presence of renal failure (n = 82).
In ACLF grade I, serum copeptin was significantly
higher in patients with renal failure (as defined by the
CLIF-C OF score [7]) at hospital admission compared
with those without (49 (21–72) vs. 23 (6–38) pmol/L;
p = 0.014). However, no significant difference in serum
copeptin was found between patients with and
without renal failure in ACLF grade II (35 (17–106) vs. 22
(13–40) pmol/L; p = 0.132). In ACLF grade III, seven out
of eight patients had renal failure (118 (42–146) pmol/L;
Fig. 1). Of all 82 patients with renal failure at admission,
47 (57.3%) patients recovered from renal failure during
follow-up (i.e., return of serum creatinine to < 2 mg/dL).
Baseline serum copeptin concentration was significantly
lower in those who recovered from renal failure during
follow-up than in those who did not (35 (14–69) vs. 59
(28–114) pmol/L; p = 0.019).
When comparing patients with and without circula-
tory failure (i.e., the use of vasopressors for circulatory
support at hospital admission according to the CLIF-
COF score; n = 22), serum copeptin levels were found to
be significantly higher in the circulatory failure group
(42 (11–64) vs. 13 (5–31) pmol/L; p = 0.002). In addition,
a weak but statistically significant inverse correlation be-
tween serum copeptin and MAP and DBP at enrolment
was found. Significant correlations with serum copeptin
were also found for serum sodium and serum creatinine
concentration, WBC, INR, prothrombin time, and Child-
Pugh, MELD, and CLIF-C OF score (Table 2). Besides the
use of vasopressors, the use of beta blockers may also po-
tentially impact on serum copeptin concentrations. How-
ever, there was no significant difference in median serum
copeptin concentration between patients who did and did
not receive beta-blocker therapy (9.9 (5.0–27.3) vs. 13.4
(4.7–31.8) pmol/L; p = 0.375).
Serum copeptin measurements during follow-up and
relation with clinical outcome
Sequential serum samples for copeptin measurement
were available for 421 out of 779 patients included in
the study; 179 patients had a sample available at both
days 0–2 and 3–7, and 85 patients had samples available
at days 0–2, 3–7, and 8–14. Overall serum copeptin
concentration decreased in the first week of follow-up
(Additional file 3). Delta serum copeptin in the first
week after hospital admission (i.e., serum copeptin at
days 3–7 minus serum copeptin at days 0–2) was –3
(–29 to 9) pmol/L. Median serum copeptin at days
3–7 was found to be significantly higher in ACLF patients
with a worsening or steady disease course (n = 48) during
the follow-up period of 28 days compared with patients
with improvement of the ACLF course (n = 52; 43 (21–70)
vs. 22 (10–36) pmol/L; p = 0.003) [14]. In contrast,
median serum copeptin at days 0–2 and delta copep-
tin did not significantly differ between these groups
(Additional file 4). However, in the whole study popu-
lation, median serum copeptin at days 0–2 was signifi-
cantly more elevated in ACLF patients with a worsening
or steady disease course (n = 68) compared with those
showing improvement of the disease (n = 71) during
follow-up (41 (18–91) vs. 30 (13–53) pmol/L; p = 0.030).
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Age (years) 58 ± 12 58 ± 12 58 ± 11 0.893
Gender (male) 512 (65.7) 421 (65.8) 91 (65.5) 0.944
Background
Diabetes 190 (24.9) 151 (24.0) 39 (29.1) 0.219
Coronary heart disease 37 (5.1) 30 (5.0) 7 (5.5) 0.796
Etiology
Alcohol 471 (61.0) 374 (58.9) 97 (70.8) 0.010
Hepatitis B 42 (5.7) 37 (6.2) 5 (3.8) 0.282
Hepatitis C 235 (31.9) 197 (32.7) 38 (28.4) 0.333
NAFLD 33 (4.5) 24 (4.0) 9 (6.8) 0.159
Cholestatic 17 (2.3) 15 (2.5) 2 (1.5) 0.505
Cryptogenic 43 (5.8) 40 (6.6) 3 (2.3) 0.052
Other 53 (7.2) 45 (7.5) 8 (6.1) 0.570
Physical examination
SBP (mmHg) 116 ± 18 117 ± 18 114 ± 21 0.238
DBP (mmHg) 67 ± 11 68 ± 11 63 ± 11 <0.001
MAP (mmHg) 83 ± 12 84 ± 12 80 ± 13 < 0.001
Clinical features
Ascites 691 (88.7) 557 (87.0) 134 (96.4) 0.002
Bacterial infection 177 (22.8) 134 (21.0) 43 (31.4) 0.009
SIRS 153 (19.6) 115 (18.0) 38 (27.3) 0.012
Sepsis 37 (4.8) 22 (3.5) 15 (11.0) < 0.001
HE 240 (30.8) 158 (24.7) 82 (59.0) < 0.001
ACLF grade I 80 (10.3) – 80 (57.6) –
ACLF grade II 51 (6.6) – 51 (36.7) –
ACLF grade III 8 (1.0) – 8 (5.7) –
Organ failure
Liver 97 (12.5) 45 (7.0) 52 (37.4) <0.001
Cerebral 39 (5.0) 16 (2.5) 23 (16.6) < 0.001
Circulation 22 (2.8) 5 (0.8) 17 (12.2) < 0.001
Respiratory 12 (1.5) 3 (0.5) 9 (6.5) < 0.001
Renal 82 (10.5) 0 (0.0) 82 (59.0) < 0.001
Coagulation 43 (5.5) 15 (2.3) 28 (20.1) < 0.001
Laboratory data
Copeptin (pmol/L) 13 (5–32) 11 (4–26) 33 (14–64) < 0.001
WBC (×109/L) 5.9 (4.1–9.3) 5.7 (4.0–8.3) 8.9 (5.3–13.1) < 0.001
CRP (mg/L) 18 (7–41) 16 (6–37) 26 (12–50) < 0.001
Bilirubin (mg/dL) 2.9 (1.5–6.5) 2.8 (1.5–5.5) 6.1 (2.0–16.4) < 0.001
INR 1.5 (1.3–1.8) 1.4 (1.3–1.7) 1.7 (1.4–2.2) < 0.001
Creatinine (mg/dL) 0.9 (0.7–1.4) 0.9 (0.7–1.2) 2.2 (1.0–3.1) < 0.001
Sodium (mmol/L) 135 ± 6 136 ± 5 134 ± 7 0.002
Scores
Child-Pugh 9.4 ± 2.1 9.2 ± 1.9 10.6 ± 2.2 < 0.001
MELD 18 ± 7 16 ± 5 26 ± 7 < 0.001
CLIF-C OF 7.5 ± 1.7 7.0 ± 1.1 9.9 ± 1.9 < 0.001
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No correlations were found with delta copeptin and delta
values of markers of renal and liver function, blood pres-
sure, inflammation, and MELD and CLIF-C OF scores
(Additional file 5).
Delta copeptin in the first week after hospital ad-
mission was found not to be associated with survival
in the subgroup of 179 patients with serum samples
available at both days 0–2 and 3–7.
Survival analysis
At 28 days after enrolment in the study, 63 (8.1%) pa-
tients had died and 24 (3.1%) had received a liver trans-
plantation. After 90 days of follow-up, 132 (16.9%)
patients had died and 63 (8.1%) were transplanted.
Serum copeptin was consistently found to be signifi-
cantly higher in patients who died or were transplanted
as compared to those who were still alive without liver









ICU admission 102 (13.2) 75 (11.8) 27 (19.4) 0.016
Antibiotics 142 (18.8) 111 (17.9) 31 (23.0) 0.170
Transfusionc 87 (11.5) 67 (10.7) 20 (14.8) 0.175
Vasoactive agentsd 39 (5.1) 21 (3.4) 18 (13.3) < 0.001
Mechanical ventilation 14 (1.8) 9 (1.4) 5 (3.6) 0.078
Renal replacement therapy 3 (0.4) 1 (0.2) 2 (1.4) 0.027
Variables are expressed as mean ± SD, median (interquartile range), or n (%) as appropriate
aComparisons between patients with and without ACLF
bAt any time during follow-up
cIncludes transfusion of red cells package, fresh-frozen plasma, platelets, and cryoprecipitates.
dIncludes any vasoactive drug used for circulatory support, variceal bleeding, or hepatorenal syndrome
ACLF acute-on-chronic liver failure, CLIF-C OF chronic liver failure-consortium organ failure, CRP C-reactive protein, DBP diastolic blood pressure,
HE hepatic encephalopathy, ICU intensive care unit, INR international normalized ratio, MAP mean arterial blood pressure, MELD Model for End-stage
Liver Disease, NAFLD non-alcoholic fatty liver disease, SBP systolic blood pressure, SIRS systemic inflammatory response syndrome, WBC white blood
cell count
Fig. 1 Association of ACLF grades with serum copeptin concentration and the presence of renal failure. Distribution of serum copeptin concentration
within subgroups of patients with acute-on-chronic liver failure (ACLF) and patients with and without ascites and no ACLF at time of admission for
acute decompensation of cirrhosis. Dots represent serum copeptin concentrations of individual patients. Horizontal lines denote median values
Kerbert et al. Critical Care  (2017) 21:321 Page 5 of 11
transplantation at 28 and 90 days follow-up (28 days, 39
(18–68) vs. 12 (4–28) pmol/L, p < 0.001; 90 days, 27
(11–56) vs. 11 (4–26) pmol/L, p < 0.001).
Results of univariate competing risk survival analysis
of clinical and laboratory data in relation to 28- and 90-
day mortality are shown in Additional files 6 and 7, re-
spectively. A strong association was found for serum
copeptin concentration at days 0–2 and survival at both
time points.
In multivariate analysis, copeptin together with WBC
and MELD or CLIF-C OF score was found to inde-
pendently predict 28-day mortality (Table 3). Moreover,
C-indices of the MELD and CLIF-C OF score for pre-
dicting 28-day mortality improved significantly by
incorporating serum copeptin (p = 0.004 and p = 0.037,
respectively; Table 4).
At 90-days of follow-up, copeptin was found to be an
independent predictive factor for mortality as well,
together with the CLIF-C OF score, age, WBC, and
serum sodium concentration (Table 3, model 2). How-
ever, in the MELD score model, copeptin was found
not to be an independent predictive factor for mortality
at this time point (Table 3, model 1). At 90 days of
follow-up, C-indices of the MELD and CLIF-C OF
score for predicting mortality did not significantly im-
prove by incorporating serum copeptin (p = 0.160 and
p = 0.077, respectively; Table 4).
Figure 2 shows the estimated probability of death after
28 and 90 days of follow-up using the CLIF-C OF score
and stratification according to serum copeptin concen-
tration, showing that high serum copeptin concentra-
tions have an additional negative impact on mortality
risk. The optimal cut-off point of serum copeptin in pre-
dicting mortality at 28 and 90 days used in Fig. 2 was
calculated using the Youden Index.
Finally, a multivariate binary logistic regression model
was performed in order to identify the independent pre-
dictive factors for ACLF development within 28 days of
follow-up (n = 71). Serum copeptin, together with WBC
and INR, was found to be an independent predictive
factor for ACLF development (odds ratio (OR) 1.40,
95% confidence interval (CI) 1.09–1.80; p = 0.009)
(Additional file 8). With the use of the Youden Index we
defined an optimal cut-off point of serum copeptin of 13.6
pmol/L in predicting ACLF development during follow-up.
In multivariate analysis, serum copeptin > 13.6 pmol/L
Table 2 Associations of clinical parameters and prognostic
scoring systems with serum copeptin concentration
Variable Correlation coefficient
with serum copeptin (r)
p value
Age 0.188 < 0.001
Scores
Child-Pugh 0.213 < 0.001
MELD 0.276 < 0.001
CLIF-C OF 0.203 < 0.001
Laboratory data
WBCa 0.228 < 0.001
Bilirubina 0.064 0.075
Prothrombin timea 0.216 < 0.001
INRa 0.100 0.006






aVariable was log-transformed prior to statistical analysis
CLIF-C OF chronic liver failure-consortium organ failure, DBP diastolic blood
pressure, INR international normalized ratio, MAP mean arterial blood pressure,
MELD Model for End-stage Liver Disease, SBP systolic blood pressure,
WBC white blood cell count
Table 3 Independent predictive factors of 28-day and 90-day
mortality in 779 patients admitted for acute decompensation of
cirrhosis; multivariate analysis
HR (95% CI) p value
Mortality at 28 days
Model 1: MELD score
MELD score 1.10 (1.06–1.14) < 0.001
Copeptina 1.55 (1.20–2.01) < 0.001
WBCa 1.82 (1.23–2.95) 0.014
Model 2: CLIF-C OF score
CLIF-C OF score 1.43 (1.25–1.64) < 0.001
Copeptina 1.53 (1.19–1.97) 0.001
WBCa 1.92 (1.18–3.13) 0.009
Mortality at 90 days
Model 1: MELD score
MELD score 1.11 (1.07–1.15) < 0.001
Copeptina 1.15 (0.97–1.37) 0.113
Age 1.03 (1.01–1.05) 0.006
WBCa 1.77 (1.26–2.47) < 0.001
Sodium 0.96 (0.93–0.99) 0.041
Model 2: CLIF-C OF score
CLIF-C OF score 1.39 (1.23–1.56) < 0.001
Copeptina 1.22 (1.02–1.45) 0.032
Age 1.02 (1.00–1.04) 0.032
WBCa 1.87 (1.32–2.65) < 0.001
Sodium 0.95 (0.92–0.98) 0.002
aVariable was log-transformed prior to statistical analysis
CI confidence interval, CLIF-C OF chronic liver failure-consortium organ failure,
HR hazard ratio, MELD Model for End-stage Liver Disease, WBC white blood
cell count
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remained a predictor of ACLF development, independently
of WBC and INR (OR 2.94, 95% CI 1.67–5.16; p < 0.001)
(Additional file 8).
Discussion
In this study, we assessed the prognostic ability of
copeptin, a surrogate marker of AVP, in patients admit-
ted for AD of cirrhosis or ACLF. The results demon-
strate that the presence of ACLF is accompanied by
significantly higher serum copeptin levels at admission
compared with those with traditional AD. In addition,
serum copeptin was found to be independently associ-
ated with short-term outcome and was shown to provide
additional prognostic information to the MELD and
CLIF-C OF scores.
The ideal prognostic biomarker for predicting short-
term ACLF development and mortality in patients with
AD is one that is elevated at the time of onset of AD, is
involved in the pathophysiology of disease progression,
and can therefore help in directing and monitoring ther-
apy. Markers reflecting hemodynamic systemic changes
in cirrhotic patients, such as the hepatic venous pressure
gradient (HVPG) and MAP, are well known to be associ-
ated with the presence of organ failure and prognosis in
cirrhosis [15–21]. In clinical practice, a prognostic bio-
marker reflecting the degree of circulatory derangement
may therefore be of importance since it may help to dis-
tinguish between patients who are at a higher risk of de-
veloping organ failure and short-term mortality. It may
also add prognostic information to conventional prog-
nostic scoring systems in cirrhosis, such as the MELD
and Child-Pugh score, which take into account indirect,
nonspecific, or subjective markers of hemodynamic
derangement such as ascites and creatinine concentra-
tion. Recent studies have shown an association of high
serum copeptin levels with hemodynamics, such as por-
tal hypertension (HVPG > 12 mmHg) [20] and a de-
creased cardiac output [21]. In this study, the role of
copeptin in hemodynamic homeostasis was shown by
the finding of a weak, but significant inverse correlation
between MAP and DBP with copeptin. The weakness
of this association may be explained by the fact that,
besides peripheral vasodilation, copeptin levels may
also be influenced by a number of other stimuli, such
as hyperosmolarity, physiological and psychological
stress, and medication (i.e., diuretics, beta blockers
and vasopressors) [22].
To date, the prognostic value of copeptin in the setting
of liver cirrhosis has been investigated in a few studies
[23–26]. The results of these studies show that serum
copeptin levels increase along with the severity of liver
disease, as defined by the Child-Pugh class [23, 25].
Moreover, circulating copeptin concentration was found
to predict short- and long-term transplant-free mortality
in patients with various stages of cirrhosis [23–26]. In
addition, a prospectively conducted study showed the
ability of plasma copeptin to predict the development of
cirrhosis-related complications and death within 3 months
after hospitalization [26]. However, no data have been re-
ported on the prognostic value of serum copeptin in an
unselected cohort of patients admitted for AD and ACLF.
Currently, several scoring systems are in use for risk strati-
fication in critically ill cirrhotic patients, such as the
MELD and Child-Pugh score. The CLIF-C OF score was
recently developed as a simplification of the CLIF-SOFA
score to diagnose and grade ACLF [7]. Its prognostic ac-
curacy was found to be significantly higher than that of
the MELD and Child-Pugh scores in patients with AD or
ACLF [7]. In the current study, it was shown that serum
copeptin predicts the risk for short-term mortality, inde-
pendently of the CLIF-C OF (28- and 90-day mortality)
and MELD (28-day mortality) scores. Moreover, incorpor-
ation of serum copeptin in the MELD and CLIF-C OF
scores improved their prognostic ability for 28-day mor-
tality. Serum copeptin measured at days 0–2 and 3–7 after
hospital admission was found to be associated with the
course of ACLF during short-term follow-up. Finally,
serum copeptin at days 0–2 after hospital admission was
found to independently predict short-term ACLF develop-
ment. On the other hand, no association between delta
serum copeptin over time and disease course and survival
was found. This finding requires further assessment in lar-
ger prospectively conducted trials in which serum copep-
tin can be obtained in all patients at set and well-defined
time points.
Deterioration of systemic hemodynamic function is
traditionally thought to play a key role in the
Table 4 C-indices of copeptin in association with MELD score
and CLIF-C OF score at 28 days and 90 days of follow-up
C-index (95% CI) p value
Mortality at 28 days
Copeptina 0.723 (0.660–0.787)
MELD 0.766 (0.707–0.826) Reference
MELD + copeptina 0.796 (0.742–0.849) 0.004
CLIF-C OF 0.739 (0.668–0.809) Reference
CLIF-C OF + copeptina 0.798 (0.748–0.849) 0.037
Mortality at 90 days
Copeptina 0.654 (0.606–0.702)
MELD 0.749 (0.707–0.792) Reference
MELD + copeptina 0.757 (0.716–0.798) 0.160
CLIF-C OF 0.699 (0.651–0.746) Reference
CLIF-C OF + copeptina 0.728 (0.686–0.771) 0.077
aVariable was log-transformed prior to statistical analysis
CLIF-C OF chronic liver failure-consortium organ failure, CI confidence interval,
MELD Model for End-stage Liver Disease
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development of multi-organ failure in ACLF [2, 3, 5].
However, in the light of new knowledge, it is now
thought that the presence of systemic inflammation in
cirrhosis is the key event in ACLF development [5].
This ‘systemic inflammation hypothesis’ proposes that
ACLF develops as a result of aggravation of systemic
inflammation and associated systemic circulatory dys-
function which is already present in AD. This hypoth-
esis was tested in a recent study by Clarìa et al. [27].
The authors found that AD is associated with very high
plasma levels of cytokines and oxidized albumin and that
ACLF develops when there is a further increase in these
inflammatory mediators. In addition, Clarìa et al. found
that markers of systemic circulatory dysfunction (i.e.,
copeptin and renin) were significantly more elevated in
patients with ACLF compared with those without.
Remarkably, in contrast to markers of systemic inflam-
mation, these hemodynamic biomarkers did not con-
sistently increase through ACLF grade I–III, which is
consistent with our findings. This finding suggests that
hemodynamic dysfunction is present in ACLF, but is
not directly associated with the severity of ACLF. This
implicates a role for pathophysiological mechanisms
other than circulatory dysfunction, such as systemic in-
flammation, contributing to the severity of ACLF.
Nevertheless, in the current study, copeptin was found
to be a strong and independent prognostic factor for
short-term outcome, especially at 28 days of follow-up.
Besides reflecting the activity of the AVP system due to
the systemic hemodynamic changes, the prognostic
ability of copeptin may also be explained by its non-
specificity. As mentioned previously, copeptin may be
a
b
Fig. 2 Association of the estimated probability of death using the chronic liver failure-consortium organ failure (CLIF-C OF) score at 28 days
(a) and 90 days (b) of follow-up, stratified according to serum copeptin concentration. The optimal cut-off point of serum copeptin in predicting
28- and 90-day mortality was defined using the Youden Index
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influenced by various stimuli, such as hyperosmolarity
and physiological and psychological stress [22]. In the
setting of acute hospitalization for AD or ACLF, this
non-specificity may be its strength. As the complexity
of the pathogenesis of ACLF is high, single, organ-
specific biomarkers may oversimplify the pathology of
the disease. Copeptin has been shown to be a reliable
novel marker of endogenous stress levels, mirroring
moderate stress levels more subtly than cortisol [28].
The prognostic ability of copeptin, as a marker of an
acute and generalized hemodynamic stress response,
has extensively been studied in general populations of
patients admitted to the emergency department and
ICU, showing promising results [29, 30]. For future
studies, it might be interesting to explore the prognos-
tic ability of copeptin specifically in cirrhotic patients
with AD or ACLF admitted to the ICU.
Some limitations concerning the present study have
to be considered. Firstly, plasma copeptin levels were
markedly higher in patients with ACLF and renal
failure than in ACLF patients without renal failure.
This may indicate that elevated plasma copeptin levels
may not only reflect an increased release of AVP by
the neurohypophysis, but also a decreased clearance
rate of copeptin in patients with ACLF and renal fail-
ure. Although copeptin is thought to be, at least
partly, excreted by the kidneys [9, 31], it is currently
not entirely clear how copeptin is removed from the
body. Future studies should focus on the potential
causal relationship between renal function and serum
copeptin levels and whether this impacts on the prog-
nostic ability of copeptin in these patients. Secondly,
the effect of possible confounding factors such as the
use of certain drugs was not (sufficiently) studied due
to the lack of information on use (diuretics), moment
of blood sampling and drug administration (vasopres-
sors), specification of the indication (vasopressors),
and dose (vasopressors and beta blockers). Thirdly,
consecutive copeptin measurements were only per-
formed in a limited number of patients. To further
explore copeptin as a prognostic marker in AD and
ACLF, and the prognostic ability of copeptin in pre-
dicting ACLF development, a prospectively conducted
and larger cohort study in which copeptin measure-
ments are sequentially performed would be interest-
ing. Finally, another potential confounding factor is
the presence of (cirrhotic) cardiomyopathy in this
population, especially because of the relatively large
proportion of patients with alcoholic liver disease
(61.0%). Copeptin has been found to be associated
with the presence of both acute and chronic heart
failure and is associated with prognosis [32]. There-
fore, it would be relevant to take into account cardiac
function in future studies.
Conclusions
Serum copeptin levels are significantly more increased
in patients with ACLF compared with those with tradi-
tional AD. Moreover, serum copeptin is a predictor of
mortality in cirrhotic patients admitted for AD, inde-
pendently of MELD and CLIF-COF scores. Serum
copeptin shows the potential to add relevant prognos-
tic information to these prognostic scoring systems.
Altogether, these findings suggest that serum copeptin
is an interesting potential prognostic marker in hospi-
talized cirrhotic patients with AD and ACLF.
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